<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264459</url>
  </required_header>
  <id_info>
    <org_study_id>Al0102st</org_study_id>
    <nct_id>NCT00264459</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture</brief_title>
  <official_title>A Multicentre, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-mixture in Patients With Clinically Relevant Grass Pollen Sensitivity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergopharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergopharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is performed to asses efficacy and safety of a sublingual extract of a six grass
      pollen mixture
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom and Medication Score (SMS)</measure>
    <time_frame>1.5 years of therapy</time_frame>
    <description>The primary endpoint is the change of the area under the curve (AUC, derived from an analysis period of 42 days) of the daily sum of the Symptom and Medication Score (SMS) from the baseline measurement to the measurement after 1.5 years of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Rating Scale</measure>
    <time_frame>1.5 years</time_frame>
    <description>Patients' Assessment of severity of symptoms at the end of each season on a 10 points visual rating scale (VRS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Grass Pollen Allergy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo was given the same way as a sublingual preparation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid formulation of an extract of a 6 grass pollen mixture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.
The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Grass pollen formulation</intervention_name>
    <description>Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.
The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.</description>
    <arm_group_label>Liquid formulation of an extract of a 6 grass pollen mixture</arm_group_label>
    <other_name>specific immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Specific Immunotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Rhinitis, Rhinoconjunctivitis, Positive Rast result to grass pollen, Positive skin prick
        test to grass pollen, Positive specific provocation to grass pollen,

        Exclusion Criteria:

        Serious chronic diseases, Other perennial allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ludger Klimek, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Allergopharma GmbH &amp; Co. KG</name>
      <address>
        <city>Reinbek</city>
        <zip>21465</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.allergopharma.de</url>
    <description>Leader in specific allergy research and therapy</description>
  </link>
  <results_reference>
    <citation>Worm M. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Eur Ann Allergy Clin Immunol. 2006 Dec;38(10):355-60.</citation>
    <PMID>17274520</PMID>
  </results_reference>
  <results_reference>
    <citation>Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2008 Mar;100(3):256-63.</citation>
    <PMID>18426146</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2005</study_first_submitted>
  <study_first_submitted_qc>December 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2005</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sublingual immunotherapy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Rhinitis</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

